Revance Therapeutics (RVNC) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Revance Therapeutic (RVNC) PT Lowered to $31 at Stifel
November 10, 2021 6:49 AM ESTStifel analyst Annabel Samimy lowered the price target on Revance Therapeutic (NASDAQ: RVNC) to $31.00 (from $33.00) while maintaining a Buy rating.
The analyst commented, "RVNC reported solid revenues ($19.8mn/ Cons $20.3) from steady RHA-filler sales ($18.3mn) in a seasonally difficult quarter and meaningful expansion of... More
